Biocon Q2FY23 Revenue at Rs. 2,384 Cr, Up 23 percent; Core EBITDA at Rs. 816 Cr., Up 34 percent Gross R&D Spend at Rs. 252 Crore, Up 52 percent
Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals…
Tag: Dr. Arun Chandavarkar
